Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines

References

• Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999;36:115–127.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, . Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, . Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
   PubMed Web of Science ®Google Scholar
• Bertoni F, Rinaldi A, Zucca E, Cavalli F. Update on the molecular biology of mantle cell lymphoma. Hematol Oncol 2006;24:22–27.
   PubMed Web of Science ®Google Scholar
• Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 2006;25:1620–1628.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, . The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185–197.
   PubMed Web of Science ®Google Scholar
• Chen RW, Bemis LT, Amato CM, . Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood 2008;112:822–829.
   PubMed Web of Science ®Google Scholar
• Lin TS, Blum KA, Fischer DB, . Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010;28:418–423.
   PubMed Web of Science ®Google Scholar
• Kawamata N, Chen J, Koeffler HP. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 2007;110:2667–2673.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, . Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867–4874.
   PubMed Web of Science ®Google Scholar
• Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004;431:343–349.
   PubMed Web of Science ®Google Scholar
• Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000;101:25–33.
   PubMed Web of Science ®Google Scholar
• Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 2005;123:607–620.
   PubMed Web of Science ®Google Scholar
• Nykanen A, Haley B, Zamore PD. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 2001;107:309–321.
   PubMed Web of Science ®Google Scholar
• Klier M, Anastasov N, Hermann A, . Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008;22:2097–2105.
   PubMed Web of Science ®Google Scholar
• Tiemann K, Hohn B, Ehsani A, . Dual-targeting siRNAs. RNA 2010;16:1275–1284.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Jung SH, Lai R, . Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma 2008;49:2081–2090.
   PubMed Web of Science ®Google Scholar
• Determann O, Hoster E, Ott G, . Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:2385–2387.
   PubMed Web of Science ®Google Scholar
• Salaverria I, Zettl A, Bea S, . Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007;25:1216–1222.
   PubMed Web of Science ®Google Scholar
• Kienle D, Katzenberger T, Ott G, . Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors. J Clin Oncol 2007;25:2770–2777.
   PubMed Web of Science ®Google Scholar
• Hartmann E, Fernandez V, Moreno V, . Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol 2008;26:4966–4972.
   PubMed Web of Science ®Google Scholar
• Zuckerman JE, Hsueh T, Koya RC, Davis ME, Ribas A. siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. J Invest Dermatol 2011;13:453–460.
   Web of Science ®Google Scholar
• Sioud M. What are the key targeted delivery technologies of siRNA now? Methods Mol Biol 2010;629:93–107.
   PubMedGoogle Scholar
• Zhou J, Li H, Li S, Zaia J, Rossi JJ. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008; 16:1481–1489.
   PubMed Web of Science ®Google Scholar
• Shaw BR, Moussa L, Sharaf M, Cheek M, Dobrikov M. Boranophosphate siRNA-aptamer chimeras for tumor-specific downregulation of cancer receptors and modulators. Nucleic Acids Symp Ser (Oxf) 2008;(52):655–656.
   PubMedGoogle Scholar
• McNamara JO 2nd, Andrechek ER, Wang Y, . Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24:1005–1015.
   PubMed Web of Science ®Google Scholar
• Zhou J, Rossi JJ. Aptamer-targeted cell-specific RNA interference. Silence 2010;1:4.
   PubMedGoogle Scholar
• Kumar P, Ban HS, Kim SS, . T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008;134:577–586.
   PubMed Web of Science ®Google Scholar
• Kenny GD, Kamaly N, Kalber TL, . Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. J Control Release 2011;149: 111–116.
   PubMed Web of Science ®Google Scholar
• Davis ME, Zuckerman JE, Choi CH, . Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464:1067–1070.
   PubMed Web of Science ®Google Scholar
• Tamura A, Nagasaki Y. Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles. Nanomedicine (Lond) 2010;5:1089–1102.
   PubMed Web of Science ®Google Scholar
• Lahti JM, Li H, Kidd VJ. Elimination of cyclin D1 in vertebrate cells leads to an altered cell cycle phenotype, which is rescued by overexpression of murine cyclins D1, D2, or D3 but not by a mutant cyclin D1. J Biol Chem 1997;272:10859–10869.
   PubMed Web of Science ®Google Scholar
• Kozar K, Ciemerych MA, Rebel VI, . Mouse development and cell proliferation in the absence of D-cyclins. Cell 2004;118:477–491.
   PubMed Web of Science ®Google Scholar
• Wlodarska I, Dierickx D, Vanhentenrijk V, . Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008;111:5683–5690.
   PubMed Web of Science ®Google Scholar
• Lacrima K, Valentini A, Lambertini C, . In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 2005;16:1169–1176.
   PubMed Web of Science ®Google Scholar